Inventiva - IVA Enterprise Value-to-Revenue Multiple

Public company logo of Inventiva SA (IVA)

The macro resilience of Inventiva S.A. (IVA) is based on the non-cyclical nature of biopharmaceuticals, where development remains independent of economic cycles. The company's price-to-sales dynamics visualize this trend, while 11853000.00 captures the current state of the parameter. The issuer's prospects rely on FDA approval of lanifibranor and a potential buyout. Massive unmet demand in the NASH treatment segment creates potential for long-term growth.

IVA: Inventiva SA Company Value to Revenue 11/23/2025 - 11/20/2026

Financial and market metric breakdowns for Inventiva Pharma (IVA)

- share price and expert price forecast:
Fundamental company valuation:IVA - Inventiva
Original product of Inventiva SA

This metric compares the total business value to sales volume, excluding the impact of debt obligations. It determines the market revaluation of assets during periods of demand volatility, identifying either undervaluation or systemic decline. For Inventiva S.A. (IVA), this calculation reflects capitalization potential through a unique steatohepatitis therapy. Analyzing the change in the company's enterprise value-to-revenue ratio allows for an assessment of market expectations regarding expansion into a multi-billion dollar segment.